David Spriggs, MD
Repertoire Immune Medicines
3
0
0
N/A
0
2
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
You Lu, MD
West China Hospital
Shared therapeutic areas:
Tanya Trippett, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
David Avigan, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
All 3 trials loaded